Performance of Interferon-γ Release Assays in Patients with Mycobacterium kansasii Infection

References

• Mazurek GH, Jereb J, Vernon A., et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010;59:1–25.
   PubMedGoogle Scholar
• Sotgiu G, Saderi L, Petruccioli E, et al. QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. J Infect. 2019;79:444–453. doi:10.1016/j.jinf.2019.08.018
   PubMed Web of Science ®Google Scholar
• Nemes E, Rozot V, Geldenhuys H, et al. Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection. Am J Respir Crit Care Med. 2017;196:638–648. doi:10.1164/rccm.201704-0817OC
   PubMed Web of Science ®Google Scholar
• Zhang H, Xin H, Wang D, et al. Serial testing of Mycobacterium tuberculosis infection in Chinese village doctors by QuantiFERON-TB Gold Plus, QuantiFERON-TB Gold in-Tube and T-SPOT.TB. J Infect. 2019;78:305–310. doi:10.1016/j.jinf.2019.01.008
   Web of Science ®Google Scholar
• Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019;68:439–443. doi:10.15585/mmwr.mm6819a3
   PubMed Web of Science ®Google Scholar
• Santin M, Garcia-Garcia JM, Rigau D, et al. Executive Summary of the Guidelines for the Use of interferon-gamma Release Assays in the Diagnosis of Tuberculosis Infection. Arch Bronconeumol. 2016;52:477–481. doi:10.1016/j.arbres.2016.02.020
   Web of Science ®Google Scholar
• Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563–1576. doi:10.1183/13993003.01245-2015
   PubMed Web of Science ®Google Scholar
• Xu D, Han C, Wang MS, Wang JL. Increasing prevalence of non-tuberculous mycobacterial infection from 2004-2009 to 2012-2017: a laboratory-based surveillance in China. J Infect. 2018;76:422–424. doi:10.1016/j.jinf.2017.12.007
   Web of Science ®Google Scholar
• Corbett EL, Churchyard GJ, Clayton T, et al. Risk factors for pulmonary mycobacterial disease in South African gold miners. A case-control study. Am J Respir Crit Care Med. 1999;159:94–99. doi:10.1164/ajrccm.159.1.9803048
   PubMed Web of Science ®Google Scholar
• Jing H, Wang H, Wang Y, et al. Prevalence of nontuberculous mycobacteria infection, China, 2004-2009. Emerg Infect Dis. 2012;18:527–528. doi:10.3201/eid1803.110175
   PubMed Web of Science ®Google Scholar
• Yu X, Liu P, Liu G, et al. The prevalence of non-tuberculous mycobacterial infections in mainland China: systematic review and meta-analysis. J Infect. 2016;73:558–567. doi:10.1016/j.jinf.2016.08.020
   Web of Science ®Google Scholar
• Tan Y, Deng Y, Yan X, et al. Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: a prospective surveillance study. J Infect. 2021;83:46–53. doi:10.1016/j.jinf.2021.05.019
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: an Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020;71:905–913. doi:10.1093/cid/ciaa1125
   PubMed Web of Science ®Google Scholar
• Kuznetcova TI, Sauty A, Herbort CP. Uveitis with occult choroiditis due to Mycobacterium kansasii: limitations of interferon-gamma release assay (IGRA) tests (case report and mini-review on ocular non-tuberculous mycobacteria and IGRA cross-reactivity). Int Ophthalmol. 2012;32:499–506. doi:10.1007/s10792-012-9588-3
   PubMedGoogle Scholar
• Wang MS, Wang JL, Wang XF. The performance of interferon-gamma release assay in nontuberculous mycobacterial diseases: a retrospective study in China. BMC Pulm Med. 2016;16:163. doi:10.1186/s12890-016-0320-3
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:905–913. doi:10.1183/13993003.00535-2020
   Web of Science ®Google Scholar
• He Y, Zhang YA, Wang MS. Stool culture for diagnosis of nontuberculous mycobacteria pulmonary disease: an indirect evidence. J Infect. 2021;83(5):607–635. doi:10.1016/j.jinf.2021.08.002
   Web of Science ®Google Scholar
• Lin MY, Reddy TB, Arend SM, et al. Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria. Infect Immun. 2009;77:5071–5079. doi:10.1128/IAI.00457-09
   Web of Science ®Google Scholar
• Arend SM, Andersen P, van Meijgaarden KE, et al. Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis. 2000;181:1850–1854. doi:10.1086/315448
   PubMed Web of Science ®Google Scholar
• Scherrer S, Landolt P, Friedel U, Stephan R. Distribution and expression of esat-6 and cfp-10 in non-tuberculous mycobacteria isolated from lymph nodes of slaughtered cattle in Switzerland. J Vet Diagn Invest. 2019;31:217–221. doi:10.1177/1040638718824074
   Web of Science ®Google Scholar
• van Ingen J, Bendien SA, de Lange WC, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009;64:502–506. doi:10.1136/thx.2008.110957
   PubMed Web of Science ®Google Scholar
• Jankovic M, Sabol I, Zmak L, et al. Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology. Int J Tuberc Lung Dis. 2016;20:934–940. doi:10.5588/ijtld.15.0633
   PubMed Web of Science ®Google Scholar
• Kobashi Y, Mouri K, Yagi S, et al. Clinical evaluation of the QuantiFERON-TB Gold test in patients with non-tuberculous mycobacterial disease. Int J Tuberc Lung Dis. 2009;13:1422–1426.
   Web of Science ®Google Scholar
• Augustynowicz-Kopec E, Siemion-Szczesniak I, Zabost A, et al. Interferon Gamma Release Assays in Patients with Respiratory Isolates of Non-Tuberculous Mycobacteria - a Preliminary Study. Pol J Microbiol. 2019;68:15–19. doi:10.21307/pjm-2019-002
   Web of Science ®Google Scholar
• Hermansen TS, Thomsen VO, Lillebaek T, Ravn P. Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. PLoS One. 2014;9:e93986. doi:10.1371/journal.pone.0093986
   PubMed Web of Science ®Google Scholar
• Sato R, Nagai H, Matsui H, et al. Interferon-gamma release assays in patients with Mycobacterium kansasii pulmonary infection: a retrospective survey. J Infect. 2016;72:706–712. doi:10.1016/j.jinf.2016.03.011
   Web of Science ®Google Scholar
• Siegel SAR, Cavanaugh M, Ku JH, Kawamura LM, Winthrop KL. Specificity of QuantiFERON-TB Plus, a New-Generation Interferon Gamma Release Assay. J Clin Microbiol. 2018;1:56. doi:10.1128/JCM.00629-18
   Web of Science ®Google Scholar
• Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis. 2006;43:1540–1546. doi:10.1086/509327
   PubMed Web of Science ®Google Scholar
• Hur YG, Crampin AC, Chisambo C, et al. Identification of immunological biomarkers which may differentiate latent tuberculosis from exposure to environmental nontuberculous mycobacteria in children. Clin Vaccine Immunol. 2014;21:133–142. doi:10.1128/CVI.00620-13
   PubMed Web of Science ®Google Scholar
• Greinert U, Schlaak M, Rusch-Gerdes S, Flad HD, Ernst M. Low in vitro production of interferon-gamma and tumor necrosis factor-alpha in HIV-seronegative patients with pulmonary disease caused by nontuberculous mycobacteria. J Clin Immunol. 2000;20:445–452.
   PubMed Web of Science ®Google Scholar
• Rae W, Gao Y, Eren E, Doffinger R, Marshall B, Williams AP. Differential Impairment of Interferon-gamma Responses in Two Cases of Pulmonary Nontuberculous Mycobacterial Disease. Case Reports Immunol. 2016;2016:9165641. doi:10.1155/2016/9165641
   Google Scholar
• Elnaggar MM, El-Naggar MM, Abdellrazeq GS, et al. Development of an improved ESAT-6 and CFP-10 peptide-based cytokine flow cytometric assay for bovine tuberculosis. Comp Immunol Microbiol Infect Dis. 2015;42:1–7. doi:10.1016/j.cimid.2015.07.005
   PubMed Web of Science ®Google Scholar
• Yang C, Luo X, Fan L, Sha W, Xiao H, Cui H. Performance of Interferon-Gamma Release Assays in the Diagnosis of Nontuberculous Mycobacterial Diseases-A Retrospective Survey From 2011 to 2019. Front Cell Infect Microbiol. 2020;10:571230. doi:10.3389/fcimb.2020.571230
   PubMed Web of Science ®Google Scholar
• Steindor M, Stehling F, Olivier M, et al. Species-Specific Interferon-Gamma Release Assay for the Diagnosis of Mycobacterium abscessus Complex Infection. Front Microbiol. 2021;12:692395. doi:10.3389/fmicb.2021.692395
   PubMed Web of Science ®Google Scholar
• van Zyl-Smit RN, Lehloenya RJ, Meldau R, Dheda K. Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT. (®)TB and QFT-GIT). J Thorac Dis. 2016;8:482–489. doi:10.21037/jtd.2016.02.65
   Web of Science ®Google Scholar
• Du F, Xie L, Zhang Y, et al. Prospective Comparison of QFT-GIT and T-SPOT.TB Assays for Diagnosis of Active Tuberculosis. Sci Rep. 2018;8:5882. doi:10.1038/s41598-018-24285-3
   PubMed Web of Science ®Google Scholar
• Chee CB, Gan SH, Khinmar KW, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. J Clin Microbiol. 2008;46:1935–1940. doi:10.1128/JCM.02403-07
   PubMed Web of Science ®Google Scholar
• Chee CB, KhinMar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J. 2010;36:355–361. doi:10.1183/09031936.00151309
   Web of Science ®Google Scholar